Literature DB >> 30279600

Cancer immunologists scoop medicine Nobel prize.

Heidi Ledford, Holly Else, Matthew Warren.   

Abstract

Entities:  

Keywords:  Cancer; Medical research; Physiology

Mesh：

Substances：

Year:  2018        PMID： 30279600     DOI： 10.1038/d41586-018-06751-0

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  3 in total

1.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

2.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

Authors:  James Larkin; Vanna Chiarion-Sileni; Rene Gonzalez; Jean Jacques Grob; C Lance Cowey; Christopher D Lao; Dirk Schadendorf; Reinhard Dummer; Michael Smylie; Piotr Rutkowski; Pier F Ferrucci; Andrew Hill; John Wagstaff; Matteo S Carlino; John B Haanen; Michele Maio; Ivan Marquez-Rodas; Grant A McArthur; Paolo A Ascierto; Georgina V Long; Margaret K Callahan; Michael A Postow; Kenneth Grossmann; Mario Sznol; Brigitte Dreno; Lars Bastholt; Arvin Yang; Linda M Rollin; Christine Horak; F Stephen Hodi; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2015-05-31       Impact factor: 91.245

3.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245
  3 in total
  36 in total

Review 1.  Advancing Tumor Microenvironment Research by Combining Organs-on-Chips and Biosensors.

Authors:  Isabel Calejo; Marcel Alexander Heinrich; Giorgia Zambito; Laura Mezzanotte; Jai Prakash; Liliana Moreira Teixeira
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

2.  Bioinformatics analysis of the role of aldolase A in tumor prognosis and immunity.

Authors:  Wanjia Tian; Junying Zhou; Mengyu Chen; Luojie Qiu; Yike Li; Weiwei Zhang; Ruixia Guo; Ningjing Lei; Lei Chang
Journal:  Sci Rep       Date:  2022-07-08       Impact factor: 4.996

3.  Data-driven design of targeted gene panels for estimating immunotherapy biomarkers.

Authors:  Jacob R Bradley; Timothy I Cannings
Journal:  Commun Biol       Date:  2022-02-23

Review 4.  The foundations of immune checkpoint blockade and the ipilimumab approval decennial.

Authors:  Alan J Korman; Sarah C Garrett-Thomson; Nils Lonberg
Journal:  Nat Rev Drug Discov       Date:  2021-12-22       Impact factor: 112.288

Review 5.  PD-L1 and B7-1 Cis-Interaction: New Mechanisms in Immune Checkpoints and Immunotherapies.

Authors:  Christopher D Nishimura; Marc C Pulanco; Wei Cui; Liming Lu; Xingxing Zang
Journal:  Trends Mol Med       Date:  2020-11-13       Impact factor: 11.951

Review 6.  Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups.

Authors:  Lawrence P Andrews; Hiroshi Yano; Dario A A Vignali
Journal:  Nat Immunol       Date:  2019-10-14       Impact factor: 25.606

7.  PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy.

Authors:  Pottayil G Sasikumar; Naremaddepalli S Sudarshan; Srinivas Adurthi; Raghuveer K Ramachandra; Dodderi S Samiulla; Anirudha Lakshminarasimhan; Anuradha Ramanathan; Talapaneni Chandrasekhar; Amit A Dhudashiya; Sumalatha R Talapati; Nagesh Gowda; Sreenivasulareddy Palakolanu; Jiju Mani; Bandi Srinivasrao; David Joseph; Nigam Kumar; Rashmi Nair; Hanudatta S Atreya; Nagaraj Gowda; Murali Ramachandra
Journal:  Commun Biol       Date:  2021-06-08

Review 8.  Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors.

Authors:  Praveen Vikas; Nicholas Borcherding; Adithya Chennamadhavuni; Rohan Garje
Journal:  Front Oncol       Date:  2020-04-28       Impact factor: 6.244

9.  Blockade of checkpoint receptor PVRIG unleashes anti-tumor immunity of NK cells in murine and human solid tumors.

Authors:  Yangyang Li; Yu Zhang; Guoshuai Cao; Xiaodong Zheng; Cheng Sun; Haiming Wei; Zhigang Tian; Weihua Xiao; Rui Sun; Haoyu Sun
Journal:  J Hematol Oncol       Date:  2021-06-26       Impact factor: 17.388

10.  Bibliometrics Analysis of Butyrophilins as Immune Regulators [1992-2019] and Implications for Cancer Prognosis.

Authors:  Yixi Wang; Na Zhao; Xianwen Zhang; Zhenhua Li; Zheng Liang; Jinrong Yang; Xingyu Liu; Yangzhe Wu; Kebing Chen; Yunfei Gao; Zhinan Yin; Xuejia Lin; Haibo Zhou; Dongbo Tian; Yang Cao; Jianlei Hao
Journal:  Front Immunol       Date:  2020-06-30       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.